Trial Outcomes & Findings for A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971) (NCT NCT00552617)
NCT ID: NCT00552617
Last Updated: 2019-11-25
Results Overview
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
100 participants
Primary outcome timeframe
Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)
Results posted on
2019-11-25
Participant Flow
Caucasian participants who had a surgical procedure using a general anesthesia of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block were enrolled in this study.
Participant milestones
| Measure |
Rocuronium + Placebo
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
|
Overall Study
Treated
|
10
|
10
|
9
|
10
|
10
|
10
|
10
|
10
|
10
|
9
|
|
Overall Study
COMPLETED
|
10
|
10
|
9
|
9
|
10
|
8
|
10
|
10
|
8
|
9
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
1
|
1
|
0
|
2
|
0
|
0
|
2
|
1
|
Reasons for withdrawal
| Measure |
Rocuronium + Placebo
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Not Treated
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
0
|
1
|
0
|
2
|
0
|
0
|
2
|
0
|
Baseline Characteristics
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
Baseline characteristics by cohort
| Measure |
Rocuronium + Placebo
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Total
n=98 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
50 Years
STANDARD_DEVIATION 7 • n=5 Participants
|
52 Years
STANDARD_DEVIATION 7 • n=7 Participants
|
50 Years
STANDARD_DEVIATION 9 • n=5 Participants
|
49 Years
STANDARD_DEVIATION 8 • n=4 Participants
|
49 Years
STANDARD_DEVIATION 13 • n=21 Participants
|
48 Years
STANDARD_DEVIATION 10 • n=10 Participants
|
47 Years
STANDARD_DEVIATION 9 • n=115 Participants
|
46 Years
STANDARD_DEVIATION 9 • n=6 Participants
|
45 Years
STANDARD_DEVIATION 10 • n=6 Participants
|
47 Years
STANDARD_DEVIATION 10 • n=64 Participants
|
48 Years
STANDARD_DEVIATION 9 • n=17 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
8 Participants
n=10 Participants
|
7 Participants
n=115 Participants
|
7 Participants
n=6 Participants
|
7 Participants
n=6 Participants
|
7 Participants
n=64 Participants
|
70 Participants
n=17 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
3 Participants
n=115 Participants
|
3 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
2 Participants
n=64 Participants
|
28 Participants
n=17 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
10 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
10 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
10 Participants
n=10 Participants
|
10 Participants
n=115 Participants
|
10 Participants
n=6 Participants
|
10 Participants
n=6 Participants
|
9 Participants
n=64 Participants
|
98 Participants
n=17 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
PRIMARY outcome
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)Population: All randomized participants who received sugammadex or placebo; without any protocol violations, and who had at least one post baseline efficacy measurement, who had a TOF trace, had a reliable TOF trace, and where drug administration did not interfere with the effect of rocuronium or vecuronium.
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.
Outcome measures
| Measure |
Rocuronium + Placebo
n=7 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=8 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=7 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
|
96.30 Minutes
Standard Deviation 33.13
|
16.30 Minutes
Standard Deviation 20.60
|
4.62 Minutes
Standard Deviation 5.97
|
1.43 Minutes
Standard Deviation 0.50
|
1.50 Minutes
Standard Deviation 0.40
|
79.02 Minutes
Standard Deviation 25.97
|
35.50 Minutes
Standard Deviation 42.13
|
5.07 Minutes
Standard Deviation 2.38
|
3.42 Minutes
Standard Deviation 1.85
|
3.03 Minutes
Standard Deviation 2.18
|
SECONDARY outcome
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)Population: All randomized participants who received sugammadex or placebo; without any protocol violations, and who had at least one post baseline efficacy measurement, who had a TOF trace, had a reliable TOF trace, and where drug administration did not interfere with the effect of rocuronium or vecuronium.
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.
Outcome measures
| Measure |
Rocuronium + Placebo
n=7 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=8 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7
|
65.67 Minutes
Standard Deviation 35.73
|
3.08 Minutes
Standard Deviation 2.25
|
2.08 Minutes
Standard Deviation 1.12
|
1.12 Minutes
Standard Deviation 0.40
|
1.02 Minutes
Standard Deviation 0.12
|
58.12 Minutes
Standard Deviation 21.90
|
12.57 Minutes
Standard Deviation 24.48
|
2.35 Minutes
Standard Deviation 0.48
|
2.00 Minutes
Standard Deviation 1.25
|
1.70 Minutes
Standard Deviation 0.55
|
SECONDARY outcome
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)Population: All randomized participants who received sugammadex or placebo; without any protocol violations, and who had at least one post baseline efficacy measurement, who had a TOF trace, had a reliable TOF trace, and where drug administration did not interfere with the effect of rocuronium or vecuronium.
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.
Outcome measures
| Measure |
Rocuronium + Placebo
n=7 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=8 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8
|
75.85 Minutes
Standard Deviation 36.65
|
6.25 Minutes
Standard Deviation 9.12
|
2.62 Minutes
Standard Deviation 1.80
|
1.28 Minutes
Standard Deviation 0.42
|
1.15 Minutes
Standard Deviation 0.25
|
64.33 Minutes
Standard Deviation 21.72
|
25.65 Minutes
Standard Deviation 35.40
|
3.10 Minutes
Standard Deviation 0.88
|
5.83 Minutes
Standard Deviation 11.43
|
2.12 Minutes
Standard Deviation 0.80
|
Adverse Events
Vecuronium + 4.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Rocuronium + Placebo
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Rocuronium + 0.5 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Rocuronium + 1.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Rocuronium + 2.0 mg/kg Sugammadex
Serious events: 1 serious events
Other events: 10 other events
Deaths: 1 deaths
Rocuronium + 4.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Vecuronium + Placebo
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Vecuronium + 0.5 mg/kg Sugammadex
Serious events: 2 serious events
Other events: 10 other events
Deaths: 0 deaths
Vecuronium + 1.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Vecuronium + 2.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Vecuronium + 4.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Rocuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Bladder tamponade
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Urinary bladder haemorrhage
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
Other adverse events
| Measure |
Vecuronium + 4.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Rocuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Shoulder pain
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Nervous system disorders
Dizziness postural
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Nervous system disorders
Migraine
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Nervous system disorders
Paralysis
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Nervous system disorders
Headache
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
30.0%
3/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Blood and lymphatic system disorders
Haemolysis
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
22.2%
2/9 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Abdominal distension
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Diarrhoea
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Flatulence
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Infrequent bowel movements
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Nausea
|
44.4%
4/9 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
50.0%
5/10 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
33.3%
3/9 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
60.0%
6/10 • Number of events 7 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
40.0%
4/10 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Gastrointestinal disorders
Vomiting
|
44.4%
4/9 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Asthenia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Catheter related complication
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Chills
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Feeling drunk
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Hypothermia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Infusion site swelling
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Oedema
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
General disorders
Pyrexia
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Infections and infestations
Candidiasis
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Infections and infestations
Ureteritis
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Airway complication of anaesthesia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Anaesthetic complication
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Operative haemorrhage
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Post procedural nausea
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Post procedural vomiting
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Postoperative constipation
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Procedural complication
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Procedural hypertension
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Procedural hypotension
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Procedural pain
|
33.3%
3/9 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
50.0%
5/10 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
33.3%
3/9 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
60.0%
6/10 • Number of events 6 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
60.0%
6/10 • Number of events 7 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
40.0%
4/10 • Number of events 6 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Wound complication
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Injury, poisoning and procedural complications
Wound secretion
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Beta 2 microglobulin increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Beta 2 microglobulin urine increased
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Beta-N-acetyl-D-glucosaminidase increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Blood glucose increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Body temperature increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Haematocrit decreased
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Haptoglobin decreased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Heart rate increased
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Neutrophil count increased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Oxygen saturation decreased
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Investigations
Protein total decreased
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Psychiatric disorders
Agitation
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Psychiatric disorders
Breath holding
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Psychiatric disorders
Initial insomnia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Psychiatric disorders
Insomnia
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Psychiatric disorders
Sleep disorder
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Bladder spasm
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Bladder tamponade
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Ketonuria
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Microalbuminuria
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Oliguria
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Polyuria
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Reproductive system and breast disorders
Genital pruritus female
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Hypoventilation
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Vascular disorders
Haemodynamic instability
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Vascular disorders
Hypertension
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Vascular disorders
Hypotension
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
|
Vascular disorders
Thrombophlebitis superficial
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All randomized participants who received study treatment
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp.
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Any scientific paper, presentation, or other communication concerning this clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.
- Publication restrictions are in place
Restriction type: OTHER